Image Source: AsiaOne
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual MeetingGlobeNewswireApril 12, 2021 PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor
Source: AsiaOne